Researchers in a major study based at Brigham and Women’s Hospital (BWH) in Boston, Massachusetts, have linked development of the deadly vascular disease pulmonary hypertension (PH) to a related family of molecules, and show that the disorder’s progression involves disparate molecular pathways that span multiple cell types. MicroRNAs…
Bayer HealthCare recently announced it will test the efficacy and safety of the drug Riociguat in patients with symptomatic pulmonary hypertension (PH) associated with idiopathic interstitial pneumonias (IIP). The study will take place at more than 50 sites in 11 countries and will include about 120 patients. Designed…
Researchers from the University of California, San Diego, presented a new study at the 2014 American Thoracic Society International Conference revealing the effects of pulmonary thromboendarterectomy (PTE) in patients with chronic pulmonary thromboembolic disease, suggesting a positive effect in patients’ conditions after the procedure. Daniel Crouch, MD, pulmonary and critical fellow…
According to recent data, there is a direct correlation between pulmonary emboli that result in the onset of pulmonary hypertension (PH) — an under recognized condition that researchers and medical practitioners alike hope to address in the PH patient population. Pulmonary embolism is the clinical condition marked by a…
Results released Monday, May 5th from Canada’s Pulmonary Hypertension Association (PHA) Patient and Caregiver Survey revealed that those in Canada diagnosed with pulmonary hypertension (PH) are experiencing serious financial, social, and physical burdens as a result of being diagnosed with disease. Chief among the difficulties experienced among the PH…
Among the fives types of PH, Pulmonary Arterial Hypertension (PAH) is recognized as a serious unmet medical need in terms of viable treatments, due to the progressive and life-threatening characteristics of the disease.  PAH patients experience symptoms where blood pressure in the pulmonary arteries is significantly heightened due to vasoconstriction, frequently…
Pulmonary hypertension (PH) is a chronic and progressive disease associated with high blood pressure in the blood vessels, known as the pulmonary arteries, that supply the lungs. The right side of the heart pumps oxygen-poor blood into the pulmonary artery. The pulmonary artery branches into smaller blood vessels in the…
Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to mosliciguat, an investigational inhalation therapy that Pulmovant is developing to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The MHLW gives this designation to experimental medicines intended to treat conditions affecting fewer than…
Insulin resistance or IR — a reduced response of body tissues to insulin, a hormone that regulates blood sugar levels — was found to correlate with disease severity in people with chronic thromboembolic pulmonary hypertension (CTEPH), according to a new study from researchers in China. Further, the team determined that…
Anoikis, a form of programmed cell death, is involved in the development of chronic thromboembolic pulmonary hypertension (CTEPH), according to a genetic analysis study. Researchers identified two anoikis-related genes associated with CTEPH — PLAUR and HMOX1 — which may serve as diagnostic biomarkers or as…
Treatments that target the prostacyclin pathway hold promise as chronic thromboembolic pulmonary hypertension (CTEPH) treatment for patients who aren’t eligible for surgery, but more data is needed to verify the effectiveness of these medications in this type of pulmonary hypertension, according to the authors of a meta-analysis of…
Get regular updates to your inbox.